OSF Ventures

OSF Ventures, established in 2015, is the corporate venture arm of OSF HealthCare, a not-for-profit Catholic health care corporation serving Illinois and Michigan since 1877. OSF Ventures invests financially and operationally in healthcare startups, focusing on health information technology, medical devices, therapeutics, diagnostics, and technology-enabled delivery services. Their mission aligns with OSF HealthCare's commitment to improving patient outcomes, enhancing patient experience, and reducing healthcare costs. OSF Ventures employs a strategic, collaborative approach, not only investing financially but also providing operational support to foster innovation and compassionate care.

Danielle Kalinsky

Senior Venture Analyst, Venture Investments

Stan Lynall

Managing Director, Venture Investments

Samuel Martin

Venture Analyst, Venture Investments

Ben Spektor

Director, Venture Investments

Mayank Taneja

Vice President, Venture Investments

49 past transactions

Hellocare

Venture Round in 2025
Hellocare is a comprehensive telehealth and virtual healthcare delivery platform that integrates software, hardware, and artificial intelligence. The company offers a range of services, including home care, primary care, virtual patient observation, remote patient monitoring, and telemedicine solutions. Its technology facilitates remote examinations and includes telemedicine carts, alerting systems, communications tools, and workflow management features. This allows healthcare providers to deliver their services from virtually any location, enhancing access to medical care for patients.

410 Medical

Series B in 2025
410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Cala Health

Series C in 2024
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

TailorMed

Series B in 2024
TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

ShiraTronics

Series B in 2024
ShiraTronics, Inc. is a company focused on developing and commercializing innovative therapies for the treatment of chronic migraines. Incorporated in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics utilizes advanced neuromodulation technology to address the unmet clinical needs of patients suffering from debilitating migraine headaches. The company's mission is to transform the lives of those affected by this widespread and disabling disorder, which impacts millions globally, by providing effective solutions that enhance their quality of life.

Inflammatix

Series E in 2024
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Pieces

Venture Round in 2024
Pieces Technologies, Inc. is a healthcare software solutions company founded in 2015 and headquartered in Dallas, Texas. The company emerged from the work of its founder, Ruben Amarasingham, MD, at Parkland Health & Hospital System, where he developed predictive models aimed at reducing patient readmissions. This initiative led to the establishment of the non-profit research institute PCCI, which has garnered over $50 million in scientific funding. Pieces Technologies functions as a dynamic center for innovation, addressing healthcare challenges for organizations worldwide by leveraging advanced predictive analytics and technology.

Huddle Up

Series C in 2024
Huddle Up is a pediatric digital health company dedicated to supporting the growth, development, and mental health of children. Founded in 2015 and based in Madison, Wisconsin, Huddle Up transforms the care experience by emphasizing peer-to-peer interactions and specialty support. The company partners with school districts to promote academic performance and facilitate social-emotional development, while also focusing on community, equity, inclusion, and belonging. Through its personalized, outcome-driven approach, Huddle Up aims to enhance the well-being of children and adolescents, fostering healthier lives.

410 Medical

Series B in 2023
410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Array Behavioral Care

Series C in 2023
Array Behavioral Care is a telepsychiatry service provider dedicated to enhancing access to quality behavioral health care through innovative technology applications. Established in 1999 by Geoffrey Boyce in New Jersey, the company offers a range of services including assessment, screening, diagnosis, consultations, and medication management. These services are delivered across various settings, from hospitals to homes, through divisions such as OnDemand Care, Scheduled Care, and AtHome Care. Array Behavioral Care aims to make mental health services convenient, affordable, and readily accessible for patients.

Cardiosense

Series A in 2022
Cardiosense is a company that focuses on developing a physiological waveform AI platform aimed at creating predictive biomarkers for disease detection and treatment. By mining raw biosignals, Cardiosense provides enhanced visibility into cardiac functions and employs advanced signal processing techniques to identify pre-symptomatic markers of cardiac disease. The company specializes in utilizing non-invasive sensors and proprietary algorithms, which allow healthcare professionals to monitor and analyze cardiac health signals effectively. This innovative approach enables the early detection of diseases, thereby facilitating improved patient care and health tracking.

410 Medical

Series B in 2022
410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Digital Diagnostics

Series B in 2022
Digital Diagnostics Inc. is an artificial intelligence diagnostics company focused on enhancing healthcare through technology. Founded in 2010 by Michael Abramoff, MD, PhD, the company has developed a suite of autonomous algorithms that analyze medical images to detect various diseases. Its flagship products include IDx-DR, which identifies diabetic retinopathy; IDx-G, which monitors glaucoma indicators; and IDx-AMD, designed to detect age-related macular degeneration. The company also offers algorithms for diagnosing conditions such as Alzheimer's disease, cardiovascular disease, and stroke risk. By providing these innovative solutions, Digital Diagnostics aims to improve the quality, accessibility, equity, and affordability of healthcare worldwide. Operating from Coralville, Iowa, the company distributes its products both domestically and internationally, striving to integrate autonomous AI into standard clinical practices and enhance patient outcomes.

Socially Determined

Series B in 2022
Socially Determined, Inc. is a technology company that specializes in risk intelligence related to social determinants of health (SDOH). Established in 2017 and headquartered in Washington, D.C., the company offers a cloud-based platform known as SocialScape. This platform utilizes social risk indices and visualizations derived from various data sources to provide insights into the dynamics of social risk. By identifying social risk drivers, Socially Determined enables organizations such as health plans, providers, life science companies, and government agencies to develop targeted intervention strategies that aim to improve health outcomes, reduce costs, and optimize utilization patterns. The company's technology facilitates the measurement and analysis of community and individual SDOH risks, allowing for a more informed approach to addressing the needs of socially and clinically complex patients.

CancerIQ

Series B in 2022
CancerIQ is a precision health technology company focused on empowering healthcare providers to identify and manage patients at high risk for cancer. Its platform offers a comprehensive suite of tools, including predictive analytics and screening resources, to help clinicians accurately stratify patient risk and guide them toward appropriate genetic testing, screening, or treatment options. The platform features a robust content library of evidence-based guidelines and risk models, facilitating informed decision-making. Additionally, CancerIQ provides digital tools for genetic test ordering and patient management, aimed at enhancing patient education and engagement. By streamlining these processes, the company enables healthcare providers to improve patient outcomes and reduce the overall cost of care through early cancer detection.

Epitel

Series A in 2022
Epitel is a digital health company focused on developing a wearable, wireless EEG monitoring platform aimed at enhancing seizure detection. The company's innovative device utilizes a proprietary cloud-based sensor system combined with advanced artificial intelligence technologies to accurately identify abnormal brain activities. By prioritizing accessibility, affordability, and reliability, Epitel enables physicians, caregivers, and patients with neurological disorders to obtain critical brain health insights, ultimately improving their quality of life and care.

TailorMed

Venture Round in 2021
TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Huddle Up

Series A in 2021
Huddle Up is a pediatric digital health company dedicated to supporting the growth, development, and mental health of children. Founded in 2015 and based in Madison, Wisconsin, Huddle Up transforms the care experience by emphasizing peer-to-peer interactions and specialty support. The company partners with school districts to promote academic performance and facilitate social-emotional development, while also focusing on community, equity, inclusion, and belonging. Through its personalized, outcome-driven approach, Huddle Up aims to enhance the well-being of children and adolescents, fostering healthier lives.

Exela Pharma Sciences

Corporate Round in 2021
Exela Pharma Sciences, LLC is a rapidly growing US-based specialty pharmaceutical company focused on the development, manufacturing, and marketing of proprietary and generic sterile injectable products. The company aims to improve patient outcomes while reducing overall healthcare costs by offering a range of products, including generic injectables, ophthalmic, and inhalation medications. With a commitment to alleviating drug shortages, Exela is recognized for its dedication to enhancing the supply chain and creating high-value employment opportunities in rural areas. By providing therapeutically effective formulations, Exela increases treatment options for healthcare providers and enhances the quality of life and treatment experience for patients.

Current Health

Series B in 2021
Current Health Limited is a healthcare technology company based in Edinburgh, United Kingdom, that specializes in wearable devices for monitoring patient vitals. Founded in 2014 and originally known as Snap40 Limited, the company rebranded in December 2018. Current Health's devices are designed to measure critical health indicators such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, enabling early identification of potential health issues. Their patient monitoring platform facilitates the management of patients at home by collecting and analyzing data to detect and predict health deterioration. This allows patients to share daily activities, report symptoms, and complete structured questionnaires, ultimately helping healthcare providers reduce risks and costs associated with patient care.

Renovia

Series C in 2021
Renovia Inc., founded in 2016 and based in Boston, Massachusetts, was a healthcare company focused on developing prescription digital therapeutics for pelvic floor disorders. The company's innovative device provided a clinically validated treatment for conditions such as stress, mixed, and urgent urinary incontinence, including overactive bladder. This technology allowed for real-time visualization of pelvic movement during muscle training sessions, facilitating a non-surgical and drug-free approach to treatment. However, Renovia ceased operations in late 2022 following a strategic review by its investors, and in January 2023, the majority of its assets, including intellectual property, were acquired by Axena Health, Inc.

Recuro Health

Venture Round in 2021
Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

Inflammatix

Series D in 2021
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Huddle Up

Series A in 2020
Huddle Up is a pediatric digital health company dedicated to supporting the growth, development, and mental health of children. Founded in 2015 and based in Madison, Wisconsin, Huddle Up transforms the care experience by emphasizing peer-to-peer interactions and specialty support. The company partners with school districts to promote academic performance and facilitate social-emotional development, while also focusing on community, equity, inclusion, and belonging. Through its personalized, outcome-driven approach, Huddle Up aims to enhance the well-being of children and adolescents, fostering healthier lives.

PhotoniCare

Series A in 2020
PhotoniCare, Inc. is a medical device company based in Champaign, Illinois, founded in 2013. The company specializes in developing innovative diagnostic tools for middle ear infections, particularly through its flagship product, the TOMi Scope. This handheld device utilizes advanced light-based technology, specifically near-infrared light waves, to provide 3D visualization of the middle ear beyond the eardrum. By enabling physicians to directly and harmlessly visualize the middle ear, PhotoniCare's technology allows for rapid assessment of middle ear conditions, assisting in determining the appropriate treatment, whether it be antibiotics or surgical intervention. The company's imaging platform also presents potential for future growth beyond otology.

VIDA

Series C in 2020
VIDA is a lung health company that modernizes respiratory care by leveraging artificial intelligence to enhance patient outcomes and streamline care coordination. The company provides healthcare organizations and physicians with advanced quantitative data intelligence and impactful visualizations, enabling effective management of patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and COVID-19. VIDA's software is FDA cleared, CE-marked, Health Canada licensed, and TGA registered, allowing for clinical use in the United States, European Economic Area, Canada, and Australia. Additionally, VIDA offers a comprehensive suite of clinical trial services, which includes advanced quantitative image analysis and support for trial data enhancement, site quality services, and subject screening, thus contributing to the acceleration of new therapies for patients.

SilverCloud Health

Series B in 2020
SilverCloud Health, established in 2011, is a digital health company that develops and provides online therapeutic solutions via tailored clinical programs. Headquartered in Boston, Massachusetts, with offices in Dublin, Ireland, and London, UK, the company's SilverCloud platform offers evidence-based, supported digital therapies to various healthcare sectors. It aims to increase client/patient engagement and reduce program dropout rates, as demonstrated by a three-fold improvement in these metrics compared to leading online therapeutic products.

CareSignal

Venture Round in 2020
CareSignal is a remote patient monitoring platform designed to enhance the performance of payers and providers in value-based care by focusing on patient engagement and early risk identification. The platform utilizes device-less technology to reach large patient populations through disease-specific, evidence-based automated communications, including text messages and phone calls. It enables care teams to receive real-time alerts that facilitate timely prioritization and proactive outreach. CareSignal is particularly committed to supporting underserved populations and safety-net providers, ensuring that patients can interact with the system using their existing phones. This approach helps care teams address chronic, behavioral, and social challenges faced by patients, promoting better health outcomes.

Health Scholars

Series B in 2020
Health Scholars, Inc. is a company that specializes in developing medical simulation training software aimed at enhancing clinical education and training for healthcare providers. Incorporated in 2017 and based in Westminster, Colorado, Health Scholars offers a range of virtual reality (VR) solutions, including pre-hospital and in-hospital advanced cardiovascular life support (ACLS) training for first responders and clinicians, respectively. Additionally, the company provides The OR, a VR training program focused on surgical fire prevention to help mitigate risks and reduce liability costs. Their platform is designed to be user-friendly and scalable across health systems, facilitating the management and delivery of interactive training content. By leveraging VR technology, Health Scholars enables healthcare professionals to engage in cost-effective and immersive training experiences that improve patient care outcomes.

Pieces

Series B in 2020
Pieces Technologies, Inc. is a healthcare software solutions company founded in 2015 and headquartered in Dallas, Texas. The company emerged from the work of its founder, Ruben Amarasingham, MD, at Parkland Health & Hospital System, where he developed predictive models aimed at reducing patient readmissions. This initiative led to the establishment of the non-profit research institute PCCI, which has garnered over $50 million in scientific funding. Pieces Technologies functions as a dynamic center for innovation, addressing healthcare challenges for organizations worldwide by leveraging advanced predictive analytics and technology.

Socially Determined

Series A in 2019
Socially Determined, Inc. is a technology company that specializes in risk intelligence related to social determinants of health (SDOH). Established in 2017 and headquartered in Washington, D.C., the company offers a cloud-based platform known as SocialScape. This platform utilizes social risk indices and visualizations derived from various data sources to provide insights into the dynamics of social risk. By identifying social risk drivers, Socially Determined enables organizations such as health plans, providers, life science companies, and government agencies to develop targeted intervention strategies that aim to improve health outcomes, reduce costs, and optimize utilization patterns. The company's technology facilitates the measurement and analysis of community and individual SDOH risks, allowing for a more informed approach to addressing the needs of socially and clinically complex patients.

410 Medical

Series A in 2019
410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

InsightRx

Series A in 2019
InsightRX is a cloud-based software platform that utilizes quantitative pharmacology and machine learning to enhance individualized treatment decisions at the point of care. Founded in 2015 by Ron Keizer, Sirj Goswami, and Ranvir Mangat, the platform provides clinicians with clinical decision support tools that optimize dosing by integrating real-time patient data, pharmacokinetic models, pharmacogenomics, and biomarkers. By analyzing both individual patient responses and population-level data, InsightRX aims to improve treatment effectiveness and directly benefit patients. The company operates from San Francisco, California, focusing on advancing the precision of medical treatment through its innovative technology.

Exo

Series B in 2019
Exo is a medical device startup focused on revolutionizing ultrasound technology for imaging and therapeutic applications. The company has developed a handheld ultrasound platform that integrates advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost advantages of semiconductor manufacturing. This approach allows Exo to provide high-quality, affordable, and user-friendly medical imaging solutions. By enabling healthcare professionals to make critical, real-time decisions, Exo aims to enhance patient outcomes significantly. The company's commitment to accessibility and ease of use in medical imaging represents a significant advancement in the field, making effective diagnostic tools available at an unprecedented price point.

Paradigm Diagnostics

Series B in 2019
Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

Gauss Surgical

Series C in 2018
Gauss Surgical, Inc. is a medical technology company that specializes in real-time blood monitoring solutions to enhance patient outcomes in surgical and obstetric settings. Founded in 2011 and headquartered in Los Altos, California, Gauss Surgical develops the Triton system, which includes various models suited for different medical needs. Triton assists healthcare professionals in monitoring and estimating blood loss during procedures, allowing for timely intervention in cases of hemorrhage. The system offers objective metrics for blood loss, thereby facilitating better clinical decision-making regarding transfusions. Serving the healthcare sector primarily in the United States, Gauss Surgical's products are designed to integrate seamlessly into existing medical practices, using sophisticated algorithms and HIPAA-compliant technology to deliver accurate monitoring in real time.

Endotronix

Series D in 2018
Endotronix Inc. is a medical technology company based in Lisle, Illinois, founded in 2007. It specializes in the development of advanced hemodynamic monitoring solutions aimed at improving the management of heart failure. The company’s flagship product is a miniaturized, wireless implantable pressure sensor that is designed to be used during interventional cardiovascular procedures. This sensor interfaces with an external measurement device and is part of a broader platform that includes a cloud-based disease management system. Through its innovative technology, Endotronix enables healthcare professionals to detect worsening heart failure earlier, facilitating proactive patient management and enhancing clinical outcomes. The company's approach connects patients, clinicians, and reimbursement teams, providing a comprehensive solution for outpatient hemodynamic management.

Renovia

Series B in 2018
Renovia Inc., founded in 2016 and based in Boston, Massachusetts, was a healthcare company focused on developing prescription digital therapeutics for pelvic floor disorders. The company's innovative device provided a clinically validated treatment for conditions such as stress, mixed, and urgent urinary incontinence, including overactive bladder. This technology allowed for real-time visualization of pelvic movement during muscle training sessions, facilitating a non-surgical and drug-free approach to treatment. However, Renovia ceased operations in late 2022 following a strategic review by its investors, and in January 2023, the majority of its assets, including intellectual property, were acquired by Axena Health, Inc.

Regroup

Series B in 2018
Regroup is a provider of integrated telepsychiatry services that facilitates remote psychiatric care through live and interactive video conferencing. The company aims to enhance access to mental health care, allowing patients to overcome barriers such as geographical distances, mobility restrictions, and the time and cost associated with in-person visits. Regroup's services prioritize patient privacy by employing end-to-end encryption to ensure the confidentiality of personal health information. By leveraging technology, Regroup addresses the growing need for accessible mental health resources in a convenient and secure manner.

Level Ex

Corporate Round in 2018
Level Ex, Inc. is a Chicago-based company that specializes in developing virtual surgery mobile applications and professional medical video games aimed at physicians. Founded in 2015, the company focuses on enhancing surgical training through innovative platforms, such as Virtual Technique Guides, which leverage multiplayer interactivity to facilitate virtual procedures in collaboration with medical device representatives. One of its notable products, Airway EX, is designed to help physicians master critical skills in endoscopic and interventional airway procedures, addressing various medical challenges such as obstructing tumors and complex intubations. By employing advanced video game technology and cognitive neuroscience, Level Ex enables healthcare professionals to stay current with rare cases, new medical devices, and evolving drug therapies, ultimately improving their surgical capabilities and decision-making skills.

PatientWisdom

Venture Round in 2017
PatientWisdom LLC, established in 2015 and headquartered in New Haven, Connecticut, operates a digital health platform that collects, curates, segments, and shares patient stories to enhance healthcare experiences and delivery. The platform offers three primary solutions: PatientWisdom facilitates understanding of patients' needs before clinical encounters; ProviderWisdom gathers insights from clinicians and staff to improve care responsiveness; CommunityWisdom provides a comprehensive view of communities for health organizations to develop or partner with programs. Serving patients, families, healthcare providers, researchers, educators, manufacturers, and payers, PatientWisdom aims to transform care by listening to stakeholders individually and at scale.

Regroup

Series A in 2017
Regroup is a provider of integrated telepsychiatry services that facilitates remote psychiatric care through live and interactive video conferencing. The company aims to enhance access to mental health care, allowing patients to overcome barriers such as geographical distances, mobility restrictions, and the time and cost associated with in-person visits. Regroup's services prioritize patient privacy by employing end-to-end encryption to ensure the confidentiality of personal health information. By leveraging technology, Regroup addresses the growing need for accessible mental health resources in a convenient and secure manner.

InsightRx

Venture Round in 2017
InsightRX is a cloud-based software platform that utilizes quantitative pharmacology and machine learning to enhance individualized treatment decisions at the point of care. Founded in 2015 by Ron Keizer, Sirj Goswami, and Ranvir Mangat, the platform provides clinicians with clinical decision support tools that optimize dosing by integrating real-time patient data, pharmacokinetic models, pharmacogenomics, and biomarkers. By analyzing both individual patient responses and population-level data, InsightRX aims to improve treatment effectiveness and directly benefit patients. The company operates from San Francisco, California, focusing on advancing the precision of medical treatment through its innovative technology.

AVIA

Series C in 2016
AVIA Inc. is a digital transformation partner for healthcare organizations, founded in 2012 and based in Chicago, Illinois. The company specializes in developing a knowledge-sharing and collaboration platform that offers market intelligence, collaborative tools, and results-based consulting services. AVIA aims to address the strategic challenges faced by healthcare providers by facilitating access to a network of health systems and strategic partners. Their platform allows healthcare leaders to research, evaluate, and select digital health solutions, while also engaging with expert consultants to guide them through the digital transformation process. This comprehensive approach enables healthcare enterprises to innovate and achieve digital success effectively.

Endotronix

Series C in 2016
Endotronix Inc. is a medical technology company based in Lisle, Illinois, founded in 2007. It specializes in the development of advanced hemodynamic monitoring solutions aimed at improving the management of heart failure. The company’s flagship product is a miniaturized, wireless implantable pressure sensor that is designed to be used during interventional cardiovascular procedures. This sensor interfaces with an external measurement device and is part of a broader platform that includes a cloud-based disease management system. Through its innovative technology, Endotronix enables healthcare professionals to detect worsening heart failure earlier, facilitating proactive patient management and enhancing clinical outcomes. The company's approach connects patients, clinicians, and reimbursement teams, providing a comprehensive solution for outpatient hemodynamic management.

BrightWater Medical

Series A in 2016
BrightWater Medical is a medical device company based in Mountain View, California, founded by Dr. Bob Smouse in 2014. The company specializes in developing innovative devices for interventional radiologists, with a focus on treating ureteral blockages. Its flagship product, the ConvertX Stent, can be converted from a catheter to a nephroureteral stent during a single procedure, eliminating the need for a second invasive intervention. This technology aims to simplify patient treatment and increase efficiency for healthcare providers. BrightWater Medical operates as a subsidiary of Merit Medical Systems.

Pieces

Series A in 2016
Pieces Technologies, Inc. is a healthcare software solutions company founded in 2015 and headquartered in Dallas, Texas. The company emerged from the work of its founder, Ruben Amarasingham, MD, at Parkland Health & Hospital System, where he developed predictive models aimed at reducing patient readmissions. This initiative led to the establishment of the non-profit research institute PCCI, which has garnered over $50 million in scientific funding. Pieces Technologies functions as a dynamic center for innovation, addressing healthcare challenges for organizations worldwide by leveraging advanced predictive analytics and technology.

Health Catalyst

Series E in 2016
Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.

Euphrates Vascular

Venture Round in 2016
Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.